Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Shanghai Pharmaceutical Co Ltd (601607) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014374
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Pharmaceutical Co Ltd (Shanghai Pharma) is a manufacturer, retailer, wholesaler and distributor of healthcare products. It carries out the research and development, manufacture and sale of pharmaceutical products for treating cancer, central nervous system (CNS) disorders and diseases related to digestive system and immuno-metabolism, cardio and cerebrovascular system and infection. The company also provides distribution and supply chain solutions to pharmaceutical manufacturers and dispensers; operates retail pharmacy stores; and provides consulting services, assets management and other services. In addition, Shanghai Pharma provides traditional Chinese medicines. The company operates through a group of subsidiaries across China. Shanghai Pharma is headquartered in Shanghai, China.

Shanghai Pharmaceutical Co Ltd (601607) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Shanghai Pharma to Acquire China Business from Cardinal Health for USD1.2 Billion 13
Partnerships 15
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 15
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 16
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 17
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 18
Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 19
Equity Offering 20
Adgero Biopharma Raises USD2 Million in Equity Financing 20
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 21
Shanghai Pharma Completes IPO For US$1.95 Billion 22
Acquisition 24
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 25
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 26
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 27
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 28
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 29
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 30
Shanghai Pharma To Acquire Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 31
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 32
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 33
Shanghai Pharma Acquires 80% Stake In Wuxi Shanhe Pharma 34
Shanghai Pharma To Acquire A Drug Company 35
Shanghai Pharma Completes Acquisition Of 65.2% Stake In China Health System 36
Shanghai Pharma Completes Acquisition Of Remaining 34.8% Stake In CITIC Pharma For US$540 Million 37
Shanghai Pharmaceutical Co Ltd – Key Competitors 38
Shanghai Pharmaceutical Co Ltd – Key Employees 39
Shanghai Pharmaceutical Co Ltd – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 42
Financial Announcements 42
Oct 30, 2017: Shanghai Pharmaceuticals Realized Stable Results In the Third Quarter 42
Aug 28, 2017: Shanghai Pharmaceuticals Realized Stable and Healthy Growth in Interim Results 43
Jun 27, 2017: Shanghai Pharmaceuticals Grew Steady in 2017 Q1 45
Mar 21, 2016: Shanghai Pharma’s 2015 Results Released 46
Corporate Communications 47
Oct 21, 2016: Shanghai Pharmaceuticals Holding Announces Changes Of The Chairman Of The Board, Member Of The Nomination Committee Of the Board And the Authorised Representative Of the Company 47
Aug 26, 2016: Shanghai Pharmaceuticals Holding Announces Resignation Of Executive Director And Proposed Appointment Of Director 49
May 07, 2016: Shanghai Pharmaceuticals Holding Announces Resignation Of Executive Director 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Shanghai Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Shanghai Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 10
Shanghai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Shanghai Pharma to Acquire China Business from Cardinal Health for USD1.2 Billion 13
Shanghai Fudan-Zhangjiang Renews Strategic Cooperation Agreement with Shanghai Pharmaceuticals 15
Shanghai Pharma to Form Joint Venture with Zhongxie Pharma 16
Shanghai Traditional Chinese Medicine Enters into Distribution Agreement with Shanghai Hutchison Pharma for Six Prescription Drug Products 17
Shanghai Pharma Enters Into R&D Agreement With Second Military Medical University To Develop New Medicine And Medical Devices 18
Pfizer Signs MOU To Form Joint Venture With Shanghai Pharma 19
Adgero Biopharma Raises USD2 Million in Equity Financing 20
Shanghai Fudan-Zhangjiang Completes Private Placement Of Shares For US$25 Million 21
Shanghai Pharma Completes IPO For US$1.95 Billion 22
Fosun International and Shanghai Pharma May Acquire Arbor Pharma 24
Shanghai Pharma Plans to Acquire 67.5% Stake in Yunnan Dali Kangya Biotech for USD43.8 Million 25
Shanghai Pharmaceuticals Acquires Stakes in Two China-Based Pharma Companies for USD71 Million 26
Shanghai Pharma To Acquire Drug Development Company For US$2.4 Million 27
Shanghai Pharma To Acquire China International Pharma For Up To US$8 Million 28
Shanghai Pharma Acquires 79% Stake In Big Global From Dongying Pharma For US$99 Million 29
Shanghai No.1 Biochemical & Pharma Acquires Additional 10.99% Stake In Mergen Biotech From Excellent Hope For US$0.2 Million 30
Shanghai Pharma To Acquire Additional 20% Stake In Chiatai Qingchun Bao Pharma For US$71 Million 31
Shanghai Pharma Completes Acquisition Of 70% Stake In Changzhou Kangli Pharma For US$33 Million 32
Shanghai Zhongxi Sunve Pharma Acquires 51% Stake In Shanghai Jinhe Bio-Technology 33
Shanghai Pharma Acquires 80% Stake In Wuxi Shanhe Pharma 34
Shanghai Pharma To Acquire A Drug Company 35
Shanghai Pharma Completes Acquisition Of 65.2% Stake In China Health System 36
Shanghai Pharma Completes Acquisition Of Remaining 34.8% Stake In CITIC Pharma For US$540 Million 37
Shanghai Pharmaceutical Co Ltd, Key Competitors 38
Shanghai Pharmaceutical Co Ltd, Key Employees 39
Shanghai Pharmaceutical Co Ltd, Subsidiaries 40

★海外企業調査レポート[Shanghai Pharmaceutical Co Ltd (601607)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報
    Summary Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product cand …
  • Kadmon Holdings Inc (KDMN):企業の財務・戦略的SWOT分析
    Kadmon Holdings Inc (KDMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • KPJ Healthcare Berhad (KPJ):企業の財務・戦略的SWOT分析
    Summary KPJ Healthcare Berhad (KPJ) is a healthcare service provider that offers medical services. The center offers services in the areas of anaesthesiology, cardiology and cardiothoracic surgery, child psychiatry, clinic pathology, occupational health services, orthopaedic and trauma surgery, diet …
  • Doosan Heavy Industries & Construction Co Ltd (034020):電力:M&Aディール及び事業提携情報
    Summary Doosan Heavy Industries & Construction Co Ltd (Doosan Heavy Industries), a subsidiary of Doosan Corporation, is a power plant equipment manufacturer. It offers integrated equipment and solutions for power and water plants. The company’s major products include boilers, generators, engines, tu …
  • Trammo Inc.:企業の戦略・SWOT・財務情報
    Trammo Inc. - Strategy, SWOT and Corporate Finance Report Summary Trammo Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Banque Degroof Petercam Private Banking:企業の戦略・SWOT・財務情報
    Banque Degroof Petercam Private Banking - Strategy, SWOT and Corporate Finance Report Summary Banque Degroof Petercam Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • International Fibres Group Ltd:企業の戦略的SWOT分析
    International Fibres Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Groupe SMCP S.A.S.:企業の戦略的SWOT分析
    Groupe SMCP S.A.S. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • KARL STORZ SE & Co KG:企業の戦略的SWOT分析
    KARL STORZ SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Stingray Digital Group Inc.:企業のM&A・事業提携・投資動向
    Stingray Digital Group Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Stingray Digital Group Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Sharjah Electricity & Water Authority:企業の戦略的SWOT分析
    Sharjah Electricity & Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Puma SE (PUM):企業の財務・戦略的SWOT分析
    Puma SE (PUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Electronic Arts Inc.:企業の戦略・SWOT・財務情報
    Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report Summary Electronic Arts Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Versum Materials, Inc. (VSM):企業の財務・戦略的SWOT分析
    Versum Materials, Inc. (VSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • China Gas Holdings Ltd (384):電力:M&Aディール及び事業提携情報
    Summary China Gas Holdings Ltd (CGHL) is a gas operator and service provider. The company offers piped natural gas, compressed natural gas, liquid petroleum gas and liquefied natural gas. Its activities include construction and operation of gas stations, gas pipeline infrastructure facilities, gas t …
  • M.D.C. Holdings Inc:戦略・SWOT・企業財務分析
    M.D.C. Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary M.D.C. Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Maybank Kim Eng Holdings Limited:企業の戦略・SWOT・財務情報
    Maybank Kim Eng Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Maybank Kim Eng Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Antaros Medical AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Antaros Medical AB (Antaros Medical) is a drug development and technology company that offers innovative MRI and PET imaging techniques for decision making in clinical drug development. The company's services include small- to medium-sized studies, decision-making in Phase 1b and Phase 2 tri …
  • Allianz Group:企業の戦略・SWOT・財務情報
    Allianz Group - Strategy, SWOT and Corporate Finance Report Summary Allianz Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Entellus Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Entellus Medical Inc (Entellus Medical), a subsidiary of Stryker Corp, is a medical device company that offers invasive products for the treatment of chronic sinusitis. The company’s products include multi sinus dilation system, surgical instruments, sinonasal suction and irrigation system, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆